ROME Italy - CSL Behring
Transcription
ROME Italy - CSL Behring
Foto MCristof for SMC media 22•ROME• Italy 24 February 2012 www. eahad2012 .org 5th EAHAD Annual Congress European Association for Haemophilia and Allied Disorders Venue Ergife Palace Hotel and Congress Centre Via Aurelia, 619 00165 Rome, Italy Language English is the official language of the Congress. No simultaneous translation will be available. Continuing medical education The 5th EAHAD Congress has been recognized by EHA-CME Unit as CME event for Hematologists and will grant 9.5 credits to attending participants. Accreditation for Italian Continuing Medical Education has also been obtained for the following specialties: haematology, medical genetics, internal medicine, pediatrics, orthopaedics, transfusion medicine, clinical pathology, biology, psycology, nursing sciences. The number of Italian CME credits granted to participants attending the whole Congress is 7.5. Liability The Congress Organizers cannot accept liability for personal injuries sustained or for loss or damage to property belonging to Congress Partecipants, either during or as a result of the Congress. Please check the validity of your insurance. 5th EAHAD www.eahad2012.org 22•24 February, 2012 Rome - Italy The Association The European Association for Haemophilia and Allied Disorders is a multi-disciplinary association of healthcare professionals who provide care for individuals with haemophilia and other bleeding disorders. EAHAD purpose is to promote clinical care, education and research for this group of patients across the continent. Visit the Association website at www.eahad.org. EAHAD Executive Committee Pier Mannuccio Mannucci, President Jan Astermark, Vice-President Philippe de Moerloose, Secretary Christopher A. Ludlam, Treasurer Gerry Dolan, Company Secretary Kathelijn Fischer Christine Harrington Cedric Hermans Johannes Oldenburg Elena Santagostino Jerzy Windyga European Association for Haemophilia and Allied Disorders Ltd Limited Company registered in England No. 06373427 Registered as a Charity in England No. 1125081 1 Wednesday, February 22nd 12.00-19.00 Registration 14.30-16.00 Satellite Symposium - Factor VIII inhibitor: the 18.00-19.30Satellite Symposium - Haemophilia with inhibitors: current state and future options Novo Nordisk Chairs: M.G. Mazzucconi (Italy), P.M. Mannucci (Italy) Introduction most cogent unresolved issue in haemophilia A. Obergfell (Switzerland) Grifols, Kedrion, LFB Early treatment means rapid bleeding control Chairs: F. Peyvandi (Italy), J. Goudemand (France) M. Morfini (Italy) Risk factors for inhibitors: can they be controlled? • In previously untreated patients The importance of treatment optimization in children E. Santagostino (Italy) E. Santagostino (Italy) • In previously treated patients Current management of ITI C. Hay (UK) M.E. Mancuso (Italy) Immune tolerance induction: the optimal choice of factor VIII product Future of haemostasis in inhibitor patients: beyond current treatment C. Escuriola Ettingshausen (Germany) 16.00-16.30 S.E. Bjørn (Novo Nordisk, Denmark) Break 16.30-18.00Satellite Symposium - Managing haemophilia for life - Thoughts on safety and efficacy Discussion and conclusions 19:30 EAHAD Executive Committee Meeting Pfizer Chairs: P.M. Mannucci (Italy), M. Makris (UK) Welcome and introduction Co-Chairmen Inhibitor development: how to assess the risk J. Astermark (Sweden) Monitoring safety and efficacy over the longterm: the role of registries K. Fischer (the Netherlands) The science of switching Thursday, February 23rd 8.00-9:30Satellite Symposium - A natural pathway to longer lasting haemophilia therapies Swedish Orphan Biovitrum and Biogen Idec Hemophilia C. Hay (UK) Chairman and Co-chair: J. Astermark (Sweden), Optimal prophylaxis in haemophilia B: new developments S. James (Sweden) L. Valentino (USA) A new age in haemophilia management Q&A Facilitated by Co-Chairmen • Chairmen introduction Summary Co-Chairmen • Extending treatment through life and disease M. Makris (UK) 2 Fc fusion technology: a new approach for drug development in haemophilia • Fc fusion technology • European Haemophilia Therapy Standardization Board (EHTSB) and the Agerelated DeVelopments And Comorbidities in haemophilia (ADVANCE) group P. Lind (Sweden) G. Dolan (UK) • Assays – A technical overview • European initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study J.M. Sommer (USA) Longer lasting coagulation factors • Clinical investigation of rFVIIIFc – a longer lasting coagulation factor VIII R. Klamroth (Germany) E. Santagostino (Italy) 12.00-12.30 Break 12.30-14.00 Lunch Satellite Symposium - Prophylaxis for life? • Individualized treatment - Coagulation factor Bayer pharmacokinetics and implications for treatment J. Pasi (UK) Chairman and Co-chair: J. Astermark (Sweden), M. Morfini (Italy) Questions and panel discussion 09.30-10.30Scientific Welcome J. Astermark (Sweden) Session 1 Interactive case discussions: • Personalized prophylaxis: a “good companion” for life Chairs: P.M. Mannucci (Italy), J. Astermark (Sweden) The European Haemophilia Safety Surveillance System (EUHASS) C. Santoro (Italy) M. Makris (UK) • Obstacles to treatment: overcoming inhibitors in prophylaxis EAHAD working parties: P.A. Holme (Norway) • IPD meta-analysis to investigate risk factors for inhibitor development Current clinical evidence R. Klamroth (Germany) A. Iorio (Italy) Pharmacokinetics – are there differences between children and adults? • EAHAD working party on mutation databases S. Björkman (Sweden) C. Ludlam (UK) Discussion and conclusion J. Astermark (Sweden), M. Morfini (Italy) • EAHAD working party on factor VIII assay discrepancies J. Oldenburg (Germany) • EAHAD working party on epidemiology and management of rare bleeding disorders F. Peyvandi (Italy) 10.30-11.00 14.00-14.30 14.30-16.00Scientific Session 2 Chairs: C.A. Ludlam (UK), J. Windyga (Poland) Break New drugs for hepatitis C: their role in haemophilia and allied disorders 11.00-12.00 Other studies: C. Colombo (Italy) • The SIPPET study: rationale and current state Outcome assessement in haemophilia therapy P.M. Mannucci (Italy) V. Blanchette (Canada) • Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe haemophilia A: the RODIN study M. van den Berg (the Netherlands) Break Ultrasound diagnosis of haemophilic arthropathy C. Martinoli (Italy) 16.00-16.30 Break 3 16.30-17.30Scientific Session 3 12.45-14.15 Chairs: C. Hermans (Belgium), M. Makris (UK) Coordinators: J. Astermark (Sweden), Prophylaxis in rare bleeding disorders E. Santagostino (Italy), J. Windyga (Poland) P. de Moerloose (Switzerland) Factor XIII deficiency: diagnostic and therapeutic issues H.P. Kohler (Switzerland) Lunch Session Poster Viewing And Manning 14.15-14.30 Break 14.30-16.00Scientific Session 6 17.30-18.30 EAHAD General Assembly Chairs: J. Oldenburg (Germany), 20.00-22.00 Congress Dinner VWF, angiodysplasia and endothelial progenitor cells: novel insights from basic science P. de Moerloose (Switzerland) A.M. Randi (UK) The value of genotyping in predicting poor response to desmopressin in mild haemophilia and von Willebrand disease Friday, February 24th 8.30-10.30Scientific Session 4 G. Castaman (Italy) Gene theraphy trial in severe haemophilia B E. Tuddenham (UK) Chairs: K. Fischer (the Netherlands), G. Dolan (UK) Tranexamic acid: the haemostatic drug of choice M. Levi (the Netherlands) Global coagulation tests: their role in haemophilia and acquired coagulation disorders Y. Dargaud (France) The ITI Study: clinical implications C. Hay (UK) The use of the clinical trial design in haemophilia: methodological considerations A. Iorio (Italy) 10.30-11.00 Break 11.00-12.30Scientific Session 5 Chairs: W. Schramm (Germany), F. Peyvandi (Italy) EMA and FDA requirements for licensing new haemophilia products: do they truly provide answers on safety/efficacy? L. Aledort (USA), E. Santagostino (Italy), C. Male (Austria) 12.30-12.45 Break Conclusions and CME questionnaire (for Italian delegates only) With the contribution of: Haemophilia Provider: Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Ufficio Formazione _ Via Francesco Sforza, 28 - 20122 Milan • Italy Organizing secretariat: SMC Media S.r.l www.smc-media.com Via Giovenale, 7 - 20136 Milan • Italy T: +39 02 3656 2222 • +39 02 5810 2846 • +39 02 8716 7183 F: +39 02 9366 3665 • C: +39 335 6530 304 E-mail: [email protected] • [email protected]